Borussertib, an AKT1 inhibitor, and a MEK inhibitor were used to treat both KRAS-mutant pancreatic and colorectal cancer cells, where the cells displayed anti-tumor activity [59]. This evidence concerns the gene AKT1 and colorectal cancer.